Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Related Articles

Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.

Cancer Res. 2017 Dec 01;77(23):6489-6498

Authors: Mills CC, Kolb EA, Sampson VB

Abstract
This review describes the pivotal roles of cell-cycle and checkpoint regulators and discusses development of specific cell-cycle inhibitors for therapeutic use for pediatric cancer. The mechanism of action as well as the safety and tolerability of drugs in pediatric patients, including compounds that target CDK4/CDK6 (palbociclib, ribociclib, and abemaciclib), aurora kinases (AT9283 and MLN8237), Wee1 kinase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented. The design of mechanism-based combinations that exploit the cross-talk of signals activated by cell-cycle arrest, as well as pediatric-focused drug development, are critical for the advancement of drugs for rare childhood diseases. Cancer Res; 77(23); 6489-98. ©2017 AACR.

PMID: 29097609 [PubMed - indexed for MEDLINE]

http://ift.tt/2CKctTW